Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: DanZ who wrote (1028)	10/5/1999 12:46:00 AM
From: Eric Fader	Read Replies (1) \| Respond to of 5582

Dan - it looked to me that someone took a whack at the stock this afternoon when the volume slowed down, a standard short-seller's strategy, but a little retracement should be considered par for the course after the nice move the past few days. I still have the sense that time is quietly ticking away, and very soon, all of a sudden---

To: DanZ who wrote (1028)	10/5/1999 9:35:00 AM
From: froche	Read Replies (1) \| Respond to of 5582

Dan, I sure hope that GUMM is a candidate for a canslim stock... It sure looks like it's on it's way... Thank you for your post.. frank

To: DanZ who wrote (1028)	10/9/1999 12:32:00 PM
From: Mark Marcellus	Read Replies (1) \| Respond to of 5582

"I noticed that you posted on the CANSLIM thread a few weeks. It seems to me that GumTech has many attributes that William O'Neil looks for in a CANSLIM stock." I know you say you're not a shill for this company Dan, but with openings like this, you sure sound like one. All in all, I think that GUMM is a prime candidate for a CANSLIM stock. What do you think? Dan, IMO that's one of the most outlandish statements you've made yet. I think you're on shaky ground with most of the CANSLIM attributes (other than the overall market), but I'm no CANSLIM expert and I could be mistaken. However, I'm quite confident that your substitution of revenues for earnings in doing the CANSLIM evaluation is dead wrong. The point of CANSLIM is to identify profitable companies with an established record of success who are poised to break out on the up side. O'Neil is quite adamant about controlling down side risk. One way you do that is to wait until companies have proven their business to be sound. Revenues don't validate the business model, earnings do. O'Neil is willing to see a stock rise quite sharply while waiting for this to happen, knowing that if the company is legit there will be plenty of money to be made after he buys in. Until this company shows real earnings, and gives every indication that those earnings will grow sharply, there is no way you can call this a CANSLIM stock.